Navigation Links
China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
Date:2/19/2013

HONG KONG, Feb. 19, 2013 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) (the "Company") today announced its plan to release financial results for the third quarter and first nine months of fiscal year 2013 on Tuesday, February 26, 2013, after market close in the US. 

The Company will host a conference call at 8:00 a.m. ET on Wednesday, February 27, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com.  A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 90798569. 

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the third quarter fiscal 2013 earnings press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:00 p.m. ET on Tuesday, February 26, 2013 and in the Company's Report on Form 6-K for the month of February 2013 available on the Securities and Exchange Commission's website at www.sec.gov.  

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit the Company¡¦s website at http://www.chinacordbloodcorp.com.  

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516
U.S. Tel: (646) 405-5185
Email: robert.koepp@icrinc.com


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
2. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
3. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
4. China Cord Blood Corporation to Further Consolidate its Corporate Structure
5. Biomaterials China News 1210 - Annual Subscription
6. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
7. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
9. China Biologic Products to Report Third Quarter 2012 Financial Results
10. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
11. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused ... pathogens,  today announced that Mary Duseau , CEO will ... March 29 at 9:50am ET. The conference will be held ... Roka Bioscience ... Roka Bioscience is a molecular diagnostics company focused ...
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis ... against cancer, autoimmune disease and more through a single-cell precision engineering platform, today ... analysis platform developed in the laboratory of Dr. James Heath at the ...
(Date:3/27/2017)... 27, 2017 Cousins Properties (NYSE: CUZ ... biotechnology companies, has signed a 10-year, approximately 125,000 square-foot lease ... asset located in the Westshore submarket of Tampa, ... Amgen has chosen Corporate Center for their new location in ... president and chief executive officer of Cousins Properties. "Amgen is ...
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small ... samples with limited tumor content in a large background of normal or wild ... the need for reliable detection of low abundance somatic mutations, particularly in small ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):